Arnon Kater and Sabina Kersting on the HOVON 158/NEXT STEP phase 2 trial testing a new first-line treatment regimen for chronic lymphocytic leukaemia
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
Arnon Kater and Sabina Kersting on the HOVON 158/NEXT STEP phase 2 trial testing a new first-line treatment regimen for chronic lymphocytic leukaemia
-
Narrated by:
-
By:
About this listen
Professor Arnon Kater and Dr Sabina Kersting join us to discuss the results of their phase 2 trial testing a new first-line treatment regimen in chronic lymphocytic leukaemia: fixed-duration ibrutinib–venetoclax followed by MRD-guided ibrutinib–obinutuzumab intensification.
Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00288-1/fulltext
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.